View Older Stories View More Recent Stories

Jul 6, 2021 08:30AM Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777
Jul 6, 2021 08:30AM Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777
Jun 21, 2021 09:00AM Agenus to Participate in the Raymond James 2021 Human Health Innovation Conference
Jun 21, 2021 09:00AM Agenus to Participate in the Raymond James 2021 Human Health Innovation Conference
Jun 17, 2021 08:31AM Agenus (AGEN) Announces U.S. FDA Acceptance and Priority Review of Balstilimab BLA for the Treatment of Recurrent or Metastatic Cervical Cancer
Jun 17, 2021 08:30AM Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer
Jun 17, 2021 08:30AM Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer
Jun 15, 2021 08:30AM Agenus Announces Virtual Annual Shareholders Meeting
Jun 15, 2021 08:30AM Agenus Announces Virtual Annual Shareholders Meeting
Jun 4, 2021 09:11AM Agenus' (AGEN) Presentations at ASCO 2021 Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373
Jun 4, 2021 09:09AM Agenus’ Presentations at ASCO 2021 Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373
Jun 4, 2021 09:09AM Agenus’ Presentations at ASCO 2021 Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373
Jun 1, 2021 04:05PM Agenus to Participate in Fireside Chat at the Jefferies 2021 Virtual Healthcare Conference
Jun 1, 2021 04:05PM Agenus to Participate in Fireside Chat at the Jefferies 2021 Virtual Healthcare Conference
May 20, 2021 07:12AM Agenus (AGEN) Presents New Data on Balstilimab and AGEN2373 in ASCO Abstracts
May 20, 2021 07:00AM Agenus Presents New Data on Balstilimab and AGEN2373 in ASCO Abstracts
May 20, 2021 07:00AM Agenus Presents New Data on Balstilimab and AGEN2373 in ASCO Abstracts
May 20, 2021 06:59AM Bristol-Myers Squibb (BMY) Elects Manuel Hidalgo Medina, M.D., Ph.D. to Board of Directors
May 20, 2021 06:59AM Bristol Myers Squibb Elects Manuel Hidalgo Medina, M.D., Ph.D. to Board of Directors
May 18, 2021 07:31AM Agenus (AGEN) and Bristol Myers Squibb (BMY) Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
May 18, 2021 07:31AM Agenus to Host Conference Call to Discuss Global Licensing Agreement with Bristol Myers Squibb for Agenus’ Anti-TIGIT Bispecific Antibody Program
May 18, 2021 07:31AM Agenus to Host Conference Call to Discuss Global Licensing Agreement with Bristol Myers Squibb for Agenus’ Anti-TIGIT Bispecific Antibody Program
May 18, 2021 07:30AM Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
May 18, 2021 07:30AM Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
May 18, 2021 07:30AM Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program
May 6, 2021 07:45AM Agenus Corporate Update and First Quarter 2021 Financial Report
May 6, 2021 07:45AM Agenus Corporate Update and First Quarter 2021 Financial Report
Apr 28, 2021 05:30PM Agenus to Present at the 2021 ASCO Annual Meeting
Apr 28, 2021 05:30PM Agenus to Present at the 2021 ASCO Annual Meeting
Apr 22, 2021 04:05PM Agenus to Provide Corporate Update and First Quarter 2021 Financial Report
Apr 22, 2021 04:05PM Agenus to Provide Corporate Update and First Quarter 2021 Financial Report
Apr 19, 2021 08:35AM Agenus (AGEN) Reports Biologics License Application Submission to FDA for Patients with Recurrent or Metastatic Cervical Cancer
Apr 19, 2021 08:30AM Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
Apr 19, 2021 08:30AM Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
Apr 14, 2021 08:30AM Agenus Doses First Cancer Patient with iNKT Cell Therapy
Apr 14, 2021 08:30AM Agenus Doses First Cancer Patient with iNKT Cell Therapy
Apr 10, 2021 08:35AM New Clinical Responses for AGEN1181 Presented at AACR
Apr 10, 2021 08:35AM New Clinical Responses for AGEN1181 Presented at AACR
Apr 6, 2021 08:30AM Agenus to Participate in Webcast Hosted by William Blair on AGEN1181 and Balstilimab AACR Presentations
Apr 6, 2021 08:30AM Agenus to Participate in Webcast Hosted by William Blair on AGEN1181 and Balstilimab AACR Presentations
Mar 15, 2021 07:45AM Agenus Corporate Update and Fourth Quarter & Full Year 2020 Financial Report
Mar 15, 2021 07:45AM Agenus Corporate Update and Fourth Quarter & Full Year 2020 Financial Report
Mar 10, 2021 04:32PM Agenus to Present New Clinical Data on AGEN1181 at AACR 2021
Mar 10, 2021 04:32PM Agenus to Present New Clinical Data on AGEN1181 at AACR 2021
Mar 2, 2021 08:30AM Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2020 Financial Report
Mar 2, 2021 08:30AM Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2020 Financial Report
Feb 9, 2021 05:06PM Andy Hurley Named Agenus Chief Commercial Officer
Feb 9, 2021 05:06PM Andy Hurley Named Agenus Chief Commercial Officer
Feb 9, 2021 11:00AM Agenus Announces Agenus Insights - Virtual R&D Miniseries
Feb 9, 2021 11:00AM Agenus Announces Agenus Insights - Virtual R&D Miniseries
View More Recent Stories View Older Stories